THE COMPANY
FOx Diagnostics was founded in 2017 as a spin-off from the MeBios research group of KU Leuven and obtained an official status of limited liability company.
In 2020 the company introduced its White Fox 1.0 system, offering real-time, label-free analysis utilizing FOx Biosystems’ revolutionary fiber-optic biosensor technology. This innovative platform increases the efficiency of bio-pharmaceutical research and development and enables its users to generate high quality biomolecular data such as affinity data, kinetic data and concentration measurements. Investors in FOx Biosystems include Heran Partners, LRM and Gemma Frisius Fund KU Leuven.
In 2020 the company introduced its White Fox 1.0 system, offering real-time, label-free analysis utilizing FOx Biosystems’ revolutionary fiber-optic biosensor technology. This innovative platform increases the efficiency of bio-pharmaceutical research and development and enables its users to generate high quality biomolecular data such as affinity data, kinetic data and concentration measurements. Investors in FOx Biosystems include Heran Partners, LRM and Gemma Frisius Fund KU Leuven.
MANAGEMENT
Interested in contacting the management or the staff? Find individual contact information here.